Guozhi Wang of the National Institute for Control Pharmaceutical & Biological Products in China will assess the effectiveness of a new inexpensive skin test that can differentiate between true Tuberculosis infection and the markers of the BCG vaccination. Because the current TB screening protocol is not sensitive enough to tell the difference, this new test could lead to earlier and better treatment options for those with early-stage infections.